Medicina
Departamento
Víctor
Asensi Álvarez
Publicaciones en las que colabora con Víctor Asensi Álvarez (38)
2024
-
Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe
Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159
2023
-
HIV medical care interruption among people living with HIV in Spain, 2004-2020
AIDS, Vol. 37, Núm. 8, pp. 1277-1284
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study
Open Forum Infectious Diseases, Vol. 8, Núm. 6
-
Mural Endocarditis: The GAMES Registry Series and Review of the Literature
Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764
-
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1678-1684
-
Self-rated health among people living with HIV in Spain in 2019: a cross-sectional study
BMC Infectious Diseases, Vol. 21, Núm. 1
2020
-
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study
AIDS Research and Therapy, Vol. 17, Núm. 1
-
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573
-
How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
HIV Medicine, Vol. 21, Núm. 2, pp. 128-134
2019
2018
-
Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 268-276
-
Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study
American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
-
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8